Immunology and Microbiology
Natural Killer Cell
100%
Chimeric Antigen Receptor Natural Killer Cell
59%
Chimeric Antigen Receptor
54%
T Cell
49%
B Cell
38%
Immunity
28%
Myeloid
25%
Chimeric Antigen Receptor T-Cell Therapy
23%
Cord Blood Stem Cell Transplantation
19%
Cytokine
18%
Effector Cell
17%
Cell Function
17%
Graft-Versus-Host Disease
16%
Immunotherapy
16%
CD19
15%
Antineoplastic Activity
14%
Hematopoietic Cell
14%
Overall Survival
13%
Progression Free Survival
13%
Immunocompetent Cell
11%
Gene Editing
11%
Umbilical Cord Blood
11%
Interleukin 10
11%
Regulatory B Cells
10%
Cytomegalovirus
10%
Interleukin 15
10%
Cell Transplantation
9%
Clustered Regularly Interspaced Short Palindromic Repeat
9%
Tumor Escape
9%
Autologous Stem Cell Transplantation
9%
STAT3
9%
Cell Subpopulation
9%
Trogocytosis
9%
Glucocorticoid
9%
Chimeric Antigen Receptor T-Cell
9%
Cancer Immunotherapy
8%
Immunosuppressive Drug
8%
Allogeneic Hematopoietic Stem Cell Transplantation
7%
Cytokine Release Syndrome
7%
Conditioning
6%
Innate Immune System
6%
Leukemia Cell
6%
CD16
6%
Lymphoma Cell
6%
Acute Graft Versus Host Disease
6%
Lineage
6%
Hematopoietic Stem Cell Transplantation
6%
Engineered Cell
6%
Mesenchymal Stem Cell
5%
Allogeneic Stem Cell Transplantation
5%
Medicine and Dentistry
Natural Killer Cell
50%
Chimeric Antigen Receptor Natural Killer Cell
42%
Chimeric Antigen Receptor
37%
Cell Therapy
35%
Chimeric Antigen Receptor T-Cell Immunotherapy
24%
Malignant Neoplasm
23%
T Cell
21%
Acute Myeloid Leukemia
20%
B Cell
15%
Transplantation
13%
Cancer
13%
Immunity
12%
Allogeneic Hematopoietic Stem Cell Transplantation
12%
Cord Blood
12%
Myelodysplastic Syndrome
11%
Effector Cell
10%
Clinical Trial
10%
Progression Free Survival
10%
Cell Transplantation
9%
Hematopoietic Cell
9%
Stem Cell Transplant
9%
Cytomegalovirus
9%
Autologous Stem Cell Transplantation
9%
Chimeric Antigen Receptor T-Cell
9%
Overall Survival
9%
Neoplasm
9%
B-Cell Chronic Lymphocytic Leukemia
8%
Graft Versus Host Reaction
8%
Cytokine Release Syndrome
8%
Cancer Immunotherapy
7%
Acute Graft Versus Host Disease
7%
Cytotoxic T-Cell
7%
Acute Lymphoblastic Leukemia
7%
Cell Function
7%
Diseases
6%
Interleukin 15
6%
Genetic Engineering
6%
Non-Hodgkin Lymphoma
5%
Acute Leukemia
5%
Ex Vivo
5%
Rituximab
5%
Hypomethylating Agent
5%
Solid Malignant Neoplasm
5%
Immunocompetent Cell
5%
Cyclophosphamide
5%
Fludarabine
5%
Immunotherapy
5%
Large-Cell Lymphoma
5%
Conditioning
5%
Keyphrases
Natural Killer Cells
73%
Chimeric Antigen Receptor T Cells (CAR-T)
49%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
41%
T Cells
24%
Acute Myeloid Leukemia
22%
Chimeric Antigen Receptor T-cell Therapy
20%
Cell Therapy
19%
Graft-versus-host Disease (GvHD)
16%
CD19
16%
Allogeneic
15%
Cord Blood
13%
Natural Killer Cell Activity
12%
Single Center
10%
Conditioning Regimen
10%
Fratricide
9%
Tumor Escape
9%
Autologous Transplantation
9%
Trogocytosis
9%
Progression-free Survival
9%
Umbilical Cord Blood Transplantation
9%
Cancer Immunotherapy
8%
Antitumor Activity
7%
Adoptive Cell Therapy
7%
B Cells
7%
Chronic Lymphocytic Leukemia
7%
Overall Survival
7%
Hematological Malignancies
6%
Myelodysplastic Syndrome
6%
Receptor Engineering
6%
Complete Remission
6%
Immune Effector Cells
6%
Oxidative Phosphorylation (OXPHOS)
6%
Diffuse Large B-cell Lymphoma (DLBCL)
6%
Natural Killer Cell Therapy
6%
Cytokine Release Syndrome
6%
Cytomegalovirus
6%
Cytotoxic T Lymphocytes
6%
MD Anderson Cancer Center
5%
Bone Marrow
5%
Interleukin-15 (IL-15)
5%
Acute Leukemia
5%
Genetic Engineering
5%
Integrin
5%
Cell Tumor
5%
Natural Killer
5%
Cytomegalovirus Reactivation
5%
Epigenetic Reprogramming
5%
Fludarabine
5%
Antigen Receptor Signaling
5%
Relapsed or Refractory Acute Myeloid Leukemia
5%